Ligand-targeted therapeutics in anticancer therapy (original) (raw)

• Carter, P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer 1, 118–129 (2001).
  CAS Google Scholar
• Huston, J. S. & George, A. J. Engineered antibodies take center stage. Hum. Antibodies 10, 127–142 (2001).
  CAS PubMed Google Scholar
• Park, J. W. et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172–1181 (2002).Carefully controlled research study that describes the therapeutic effects in xenograft breast cancer models of anti-ERBB2-targeted immunoliposomes. This might be the first immunoliposome to enter clinical trials.
  CAS PubMed Google Scholar
• Drummond, D. C., Hong, K., Park, J. W., Benz, C. C. & Kirpotin, D. B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 60, 285–332 (2000).
  CAS PubMed Google Scholar
• Senter, P. D. & Springer, C. J. Selective activation of anticancer produugs by monoclonal antibody–enzyme conjugates. Adv. Drug Deliv. Rev. 53, 247–264 (2001).
  CAS PubMed Google Scholar
• Maynard, J. & Georgiou, G. Antibody engineering. Annu. Rev. Biomed. Eng. 2, 339–376 (2000).
  CAS PubMed Google Scholar
• Noonberg, S. B. & Benz, C. C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753–767 (2000).
  CAS PubMed Google Scholar
• Borisch, B., Semac, I., Soltermann, A., Palomba, C. & Hoessli, D. C. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy. Verh. Dtsch. Ges. Pathol. 85, 161–166 (2001).
  CAS PubMed Google Scholar
• Baselga, J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61 (Suppl. 2), 14–21 (2001).
  CAS PubMed Google Scholar
• Vose, J. M. et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19, 389–397 (2001).
  CAS PubMed Google Scholar
• Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predetermined specificity. Nature 256, 495–497 (1975).
  CAS PubMed Google Scholar
• Dillman, R. O. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconjugates Radiopharm 3, 1 (1990).
  Google Scholar
• Dillman, R. O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19, 833–841 (2001).
  CAS PubMed Google Scholar
• Pavlinkova, G. et al. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int. J. Cancer 94, 717–726 (2001).
  CAS PubMed Google Scholar
• Juweid, M. et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144–5153 (1992).
  CAS PubMed Google Scholar
• Banerjee, R. K., van Osdol, W. W., Bungay, P. M., Sung, C. & Dedrick, R. L. Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue. J. Control. Release 74, 193–202 (2001).
  CAS PubMed Google Scholar
• Adams, G. P. et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750–4755 (2001).
  CAS PubMed Google Scholar
• Lopes de Menezes, D. E., Pilarski, L. M. & Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58, 3320–3330 (1998).
  CAS PubMed Google Scholar
• Ruoslahti, E. & Rajotte, D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18, 813–827 (2000).
  CAS PubMed Google Scholar
• Brekken, R. A. & Thorpe, P. E. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 21, 4221–4229 (2001).
  CAS PubMed Google Scholar
• Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–1380 (2000).
  CAS PubMed PubMed Central Google Scholar
• Ruoslahti, E. Specialization of tumor vasculature. Nature Rev. Cancer 2, 83–90 (2002).
  Google Scholar
• Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995).
  CAS PubMed Google Scholar
• Stohrerm, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251–4255 (2000).
  Google Scholar
• Yuan, F. et al. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352–3356 (1994).
  CAS PubMed Google Scholar
• Allen, T. M., Hansen, C. B. & Stuart, D. D. in Medical Applications of Liposomes (eds Lasic, D. D. & Papahadjopoulos, D.) 297–323 (Elsevier Science, Amsterdam, 1998).
  Google Scholar
• Ercan, M. T. & Caglar, M. Therapeutic radiopharmaceuticals. Curr. Pharm. Des. 6, 1085–1121 (2000).
  CAS PubMed Google Scholar
• Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693–713 (2002).
  CAS PubMed Google Scholar
• Wagner, H. N. J. et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J. Nucl. Med. 43, 267–272 (2002).
  CAS PubMed Google Scholar
• Kaminski, M. S. et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19, 3908–3911 (2001).An important clinical study showing that patients who had failed several chemotherapy regimens had significantly increased responses to RAIT compared with their last qualifying chemotherapy.
  Google Scholar
• Kaminski, M. S. et al. Iodine I131 tositumomab therapy for previously untreated follicular lymphoma. Proc. Am. Soc. Clin. Oncol. Ann. Meet. 19, Abstract 11 (2000).
  Google Scholar
• DeNardo, G. L. et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin. Lymphoma 1, 118–126 (2000).
  CAS PubMed Google Scholar
• Leonard, J. P. & Link, B. K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 29 (Suppl. 2), 81–86 (2002).
  CAS PubMed Google Scholar
• Linden, O. et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin. Cancer Res. 5, 3287s–3291s (1999).
  CAS PubMed Google Scholar
• Juweid, M. E. et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 3292s–3303s (1999).
  CAS PubMed Google Scholar
• Postema, E. J., Boerman, O. C., Oyen, W. J., Raemaekers, J. M. & Corstens, F. H. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 28, 1725–1735 (2001).
  CAS PubMed Google Scholar
• Jurcic, J. G. Antibody therapy for residual disease in acute myelogenous leukemia. Crit. Rev. Oncol. Hematol. 38, 37–45 (2001).
  CAS PubMed Google Scholar
• Burke, J. M., Jurcic, J. G. & Scheinberg, D. A. Radioimmunotherapy for acute leukemia. Cancer Control 9, 106–113 (2002).
  PubMed Google Scholar
• Dillman, R. O. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 9, 71–80 (2001).
  CAS PubMed Google Scholar
• Goldenberg, D. M. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol. 39, 195–201 (2001).
  CAS PubMed Google Scholar
• Casey, J. L. et al. Tumour targeting of humanised cross-linked divalent-Fab′ antibody fragments: a clinical phase I/II study. Br. J. Cancer 86, 1401–1410 (2002).
  CAS PubMed PubMed Central Google Scholar
• Barbet, J. et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. 14, 153–166 (1999).
  CAS PubMed Google Scholar
• Gestin, J. F. et al. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J. Nucl. Med. 42, 146–153 (2001).
  CAS PubMed Google Scholar
• Gautherot, E. et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J. Nucl. Med. 41, 480–487 (2000).
  CAS PubMed Google Scholar
• Kennel, S. J. et al. Vascular-targeted radioimmunotherapy with the alpha-particle emitter (211)at. Radiat. Res. 157, 633–641 (2002).
  CAS PubMed Google Scholar
• Duvic, M. et al. Quality-of-life improvements in cutaneous T-Cell lymphoma patients treated with denileukin diftitox (ONTAK(R)). Clin. Lymphoma 2, 222–228 (2002).
  CAS PubMed Google Scholar
• Olsen, E. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388 (2001).Clinical trial that describes the results and side effects of the only immunotoxin that has been approved so far, showing that patients with persistent or recurrent cutaneous T-cell lymphoma have a 30% response rate, but experienced a 25% rate of vascular leak syndrome.
  CAS PubMed Google Scholar
• Schindler, J., Sausville, E. A., Messmann, R., Uhr, J. W. & Vitetta, E. S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin. Cancer Res. 7, 255–258 (2001).
  CAS PubMed Google Scholar
• Multani, P. S., O'Day, S., Nadler, L. M. & Grossbard, M. L. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 4, 2599–2604 (1998).
  CAS PubMed Google Scholar
• Dinndorf, P. et al. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J. Immunother. 24, 511–516 (2001).
  CAS PubMed Google Scholar
• Grossbard, M. L. et al. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 2392–2398 (1999).
  CAS PubMed Google Scholar
• Messmann, R. A. et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin. Cancer Res. 6, 1302–1313 (2000).
  CAS PubMed Google Scholar
• Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V. & Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl Acad. Sci. USA 96, 3957–3962 (1999).An important research study showing that a three-amino-acid sequence motif in toxins is responsible for binding to and damaging endothelial cells, causing vascular leak syndrome.
  CAS PubMed PubMed Central Google Scholar
• Baluna, R., Coleman, E., Jones, C., Ghetie, V. & Vitetta, E. S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res. 258, 417–424 (2000).
  CAS PubMed Google Scholar
• Vitetta, E. S. Immunotoxins and vascular leak syndrome. Cancer J. 6, S218–S224 (2000).
  PubMed Google Scholar
• Hu, R.-G., Zhai, Q.-W., He, W.-J., Mei, L. & Liu, W.-Y. Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. Int. J. Biochem. Cell Biol. 34, 396–402 (2002).
  CAS PubMed Google Scholar
• Wei, B. R., Ghetie, M. A. & Vitetta, E. S. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin. Cancer Res. 6, 631–642 (2000).
  CAS PubMed Google Scholar
• Kreitman, R. J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2, 313–325 (2001).
  CAS PubMed Google Scholar
• Frankel, A. E. Increased sophistication of immunotoxins. Clin. Cancer Res. 8, 942–944 (2002).
  CAS PubMed Google Scholar
• Pennell, C. A. & Erickson, H. A. Designing immunotoxins for cancer therapy. Immunol. Res. 25, 177–191 (2002).
  CAS PubMed Google Scholar
• Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. 8, 995–1002 (2002).Description of the use of phage display and hot-spot mutagenesis to select mutant F V fragments that had increased cytotoxicity against anti-CD22-expressing malignant cells.
  CAS PubMed Google Scholar
• Frankel, A. E., Powell, B. L., Hall, P. D., Case, L. D. & Kreitman, R. J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. 8, 1004–1013 (2002).
  CAS PubMed Google Scholar
• Garnett, M. C. Targeted drug conjugates: principles and progress. Adv. Drug Del. Rev. 53, 171–216 (2001).
  CAS Google Scholar
• Tolcher, A. W. et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17, 478–484 (1999).
  CAS PubMed Google Scholar
• Newton, D. L., Hansen, H. J., Mikulski, S. M., Goldenberg, D. M. & Rybak, S. M. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97, 528–535 (2001).
  CAS PubMed Google Scholar
• Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).Clincial trial of the first approved immunoconjugate, showing that 30% of patients achieved remission, but a high incidence of myelosuppression and hyperbilirubinaemia was observed.
  CAS PubMed Google Scholar
• Stadtmauer, E. A. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. Clin. Lymphoma 2 (Suppl. 1), S24–S28 (2002).
  PubMed Google Scholar
• Dubowchik, G. M. & Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm. Therap. 83, 67–123 (1999).
  CAS Google Scholar
• Napier, M. P. et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 6, 765–772 (2000).
  CAS PubMed Google Scholar
• Xu, G. & McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7, 3314–3324 (2001).
  CAS PubMed Google Scholar
• Bhatia, J. et al. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int. J. Cancer 85, 571–577 (2000).Description of a new approach to ADEPT, in which both the targeting agent and the prodrug-converting enzyme are included together in a recombinant fusion protein.
  CAS PubMed Google Scholar
• Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S. & Allen, T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239, 133–144 (1995).
  PubMed Google Scholar
• Torchilin, V. P. et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via _p_-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511, 397–411 (2001).
  CAS PubMed Google Scholar
• Ishida, T., Iden, D. L. & Allen, T. M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 460, 129–133 (1999).Description of a simple new technique for converting non-targeted liposomal drugs into targeted immunoliposomes that can be tailored to individual patient disease profiles, thereby overcoming one of the manufacturing barriers to clinical trials of immunoliposomes.
  CAS PubMed Google Scholar
• Iden, D. L. & Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim. Biophys. Acta 1513, 207–216 (2001).
  CAS PubMed Google Scholar
• Moreira, J. N., Ishida, T., Gaspar, R. & Allen, T. M. Use of the post-insertion technique to insert peptide ligands into pre-formed Stealth liposomes with retention of binding activity and cytotoxicity. Adv. Drug Deliv. Rev. 19, 265–269 (2002).
  CAS Google Scholar
• Rosenecker, J. et al. Increased liposome extravasation in selected tissues: effect of substance P. Proc. Natl Acad. Sci. USA 93, 7236–7241 (1996).
  CAS PubMed PubMed Central Google Scholar
• Kong, G. et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 60, 6950–6957 (2000).
  CAS PubMed Google Scholar
• Allen, T. M. & Moase, E. H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Del. Rev. 21, 117–133 (1996).
  CAS Google Scholar
• Drummond, D. C., Meyer, O., Hong, K. L., Kirpotin, D. B. & Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691–743 (1999).
  CAS PubMed Google Scholar
• Li, W. M., Mayer, L. D. & Bally, M. B. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J. Pharmacol. Exp. Therapeut. 300, 976–983 (2002).
  CAS Google Scholar
• Allen, T. M., Sapra, P., Moase, E., Moreira, J. N. & Iden, D. L. Adventures in targeting. J. Liposome Res. 121, 5–12 (2002).
  Google Scholar
• Nielsen, U. et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591, 109–118 (2002).
  CAS PubMed Google Scholar
• Park, J. W. et al. Tumor targeting using anti-Her2 immunoliposomes. J. Control. Release 74, 95–113 (2001).
  CAS PubMed Google Scholar
• Lopes de Menezes, D. E., Pilarski, L. M., Belch, A. R. & Allen, T. M. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta 1466, 205–220 (2000).
  CAS PubMed Google Scholar
• Boman, N. L., Masin, D., Mayer, L. D., Cullis, P. R. & Bally, M. B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54, 2830–2833 (1994).
  CAS PubMed Google Scholar
• Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S. & Allen, T. M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta 1515, 144–158 (2001).
  CAS PubMed Google Scholar
• Needham, D. & Dewhirst, M. W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 53, 285–305 (2001).
  CAS PubMed Google Scholar
• Sharma, A., Straubinger, R. M., Ojima, I. & Bernacki, R. J. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. Pharm. Sci. 84, 1400–1404 (1995).
  CAS PubMed Google Scholar
• Lu, Z.-R., Shiah, J.-G., Sakuma, S., Kopeckova, P. & Kopecek, J. Design of novel bioconjugates for targeted drug delivery. J. Control. Rel. 78, 165–173 (2002).
  CAS Google Scholar
• David, A., Kopeckova, P., Rubinstein, A. & Kopecek, J. Enhanced bioorecognition and internalization of HMPA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjugate Chem. 12, 890–899 (2001).
  CAS Google Scholar
• Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002).Results of the only clinical trial so far that uses immunopolymers, demonstrating that the targeted therapy increased delivery of immunopolymers to tumours in patients with metastatic liver cancer.
  CAS PubMed Google Scholar
• Hovorka, O. et al. Differences in the intrcellular fate of free and polymer-bound doxorubicin. J. Control. Release 80, 101–117 (2002).
  CAS PubMed Google Scholar
• Lopes de Menezes, D. E., Kirchmeier, M. J., Gagne, J.-F., Pilarski, L. M. & Allen, T. M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res. 9, 199–228 (1999).
  Google Scholar
• Kirchmeier, M. J., Ishida, T., Chevrette, J. & Allen, T. M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J. Liposome Res. 11, 15–29 (2001).
  CAS PubMed Google Scholar
• Satchi, R., Connors, T. A. & Duncan, R. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070–1076 (2001).
  CAS PubMed PubMed Central Google Scholar
• Simoes, S., Slepushkin, V., Duzgunes, N. & Pedroso de Lima, M. C. On the mechanisms of internatilzation and intracellular delivery mediated by pH-sensitive liposomes. Biochim. Biophys. Acta 1515, 23–37 (2001).
  CAS PubMed Google Scholar
• Turk, M. J., Reddy, J. A., Chmielewski, J. A. & Low, P. S. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559, 56–68 (2002).
  CAS PubMed Google Scholar
• Hong, M.-S., Lim, S.-J., Oh, Y.-K. & Kim, C.-K. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J. Pharm. Pharmacol. 54, 51–58 (2002).
  CAS PubMed Google Scholar
• Pasqualini, R. et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722–727 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lee, R. J. & Low, P. S. Folate-targeted liposomes for drug delivery. J. Liposome Res. 7, 455–466 (1997).
  CAS Google Scholar
• Gabizon, A. et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. 10, 289–298 (1999).
  CAS Google Scholar
• Ishida, O. et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18, 1042–1048 (2001).
  CAS PubMed Google Scholar
• Derycke, A. S. L. & De Witte, P. A. M. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int. J. Oncol. 20, 181–187 (2002).
  CAS PubMed Google Scholar
• Brekken, R. A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60, 5117–5124 (2000).
  CAS PubMed Google Scholar
• Kreitman, R. J. et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622–1636 (2000).
  CAS PubMed Google Scholar
• Reardon, D. A. et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389–1397 (2002).
  CAS PubMed Google Scholar
• Behr, T. M. et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 (Suppl. 4), 1373–1381 (2002).
  CAS PubMed Google Scholar
• Epenetos, A. A., Hird, V., Lambert, H., Mason, P. & Coulter, C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J. Gynecol. Cancer 10 (S1), 44–46 (2000).
  Google Scholar
• Meredith, R. F. et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5 (Suppl. 10), 3254s–3258s (1999).
  CAS PubMed Google Scholar
• Wiseman, G. A. et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit. Rev. Oncol. Hematol. 39, 181–194 (2001).Important clinical study showing that RAIT with 90 yttrium Zevalin (anti-CD20) gave superior clinical outcome compared with immunotherapy with the non-radiolabelled correlate rituximab (Rituxan).
  CAS PubMed Google Scholar
• Witzig, T. E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453–2463 (2002).
  CAS PubMed Google Scholar
• Schnell, R. et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-cahin immunotoxin. Leukemia 14, 129–135 (2000).
  CAS PubMed Google Scholar
• Kreitman, R. J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241–247 (2001).
  CAS PubMed Google Scholar
• Thompson, J. et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng. 14, 1035–1041 (2001).
  CAS PubMed Google Scholar
• Engebraaten, O., Hjortland, G. O., Juell, S., Hirschberg, H. & Fodstad, O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodefficient animals. Int. J. Cancer 97, 846–852 (2002).
  CAS PubMed Google Scholar
• Strome, S. E. et al. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin. Cancer Res. 8, 281–286 (2002).
  CAS PubMed Google Scholar
• Thomas, P. B., Delatte, S. J., Sutphin, A., Frankel, A. E. & Tagge, E. P. Effective targeted cytotoxicity of neuroblastoma cells. J. Pediatr. Surg. 37, 539–544 (2002).
  PubMed Google Scholar
• Peipp, M. et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 62, 2848–2855 (2002).
  CAS PubMed Google Scholar
• Shinohara, H. et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J. Surg. Res. 102, 169–177 (2002).
  CAS PubMed Google Scholar
• Veenendaal, L. M. et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc. Natl Acad. Sci. USA 99, 7866–7871 (2002).
  CAS PubMed PubMed Central Google Scholar